“…Specifically, STRO-1+cKit+FLK-1+CD34+ cells were reported to have the highest growth potential and neurogenic commitment, while STRO-1+cK-it+CD34+ alone express significantly more low affin- [11] general: STRO-1, CD29, CD44, CD73, CD90, CD105, CD146, CD166, CD271 hematopoietic: CD34 and CD117 stemness: OCT-3/4 and NANOG [25] CD13, CD29, CD105, CD146, CD166 [1] CD90, CD73, CD34 [49] STRO-1, c-Kit, CD29, CD34, CD44, CD73, CD105, CD146 [47] STRO-1, c-Kit, CD34 [15] CD90, CD73, CD34 ity nerve growth factor receptor (LNGFR) [47,48]. Therefore, mainly STRO-1+ DPSCs show generally firmer tendency for neurogenic commitment rather than other pulp cells expressing common mesenchymal markers [49,50]. Efficiency of novel DPSC derived treatments is strongly dependent on other cofactors, with root canal treatment recently improved through establishment of silicate -based root canal sealers that exhibited better mineralization activity compared with conventional resin -based sealers [43].…”